Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 95

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 95
---
 information
which may be appropriate for presentation to us as well as to other entities to which they owe a fiduciary duty. They may also in the
future become affiliated with entities that are engaged in business or other activities similar to those we intend to conduct. As a result,
they may have conflicts of interest in determining to which entity particular opportunities or information should be presented. If, as
a result of such conflict, we are deprived of investment, business or information, the execution of our business plan and our ability
to effectively compete in the marketplace may be adversely affected.

<div align='center'>55

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus contains forward-looking
statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations
for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical
facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as
“aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,”
“objective,” “plan,” “predict,” “potential,” “positioned,” “seek,”
“should,” “target,” “will,” “would,” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking
statements include, but are not limited to, statements about:

| ● | the ability of our clinical trials to demonstrate safety and efficacy of our future product candidates, and other positive results; |

| ● | the timing and focus of our future preclinical studies and clinical trials, and the reporting of data from those studies and trials; |

| ● | the size of the market opportunity for our future product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; |

| ● | our ability to accurately identify demand for our Gelrin hydrogel platform or any future product candidates; |

| ● | the success of competing therapies that are or may become available; |

| ● | the beneficial characteristics, safety, efficacy and therapeutic effects of our future product candidates; |

| ● | our ability to obtain FDA approval for our GelrinC product and obtain and maintain regulatory approval of our future product candidates; |

| ●